This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you are not the named addressee you should not disseminate, distribute or copy this e-mail. Please notify the sender immediately by e-mail if...
The documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by...
Daniel Carlat, MDDr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
Here’s a scenario for you. You have five medications to choose from. They are all FDA approved for the same indications. Any head-to-head study among them has shown equivalent efficacy. Three of them are associated with significant weight gain, hypercholesteremia, and diabetes risk. Two of them are not. Your job is to take a stand on what you would recommend as "first-line" medication for the disorder in question.
Daniel Carlat, MDDr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
Clozapine (trade name, Clozaril) is a drug that none of us would prescribe if all things were equal. With the potentially catastrophic side effect of agranulocytosis, along with a metabolic side effect profile worse even than Zyprexa’s, the only reason to expose living beings to this medication is that it is reputed to be the most effective antipsychotic under the sun. But is it?
Daniel Carlat, MDDr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
We knew it was about to happen. We just didn’t know it would happen all at once. Between July and September of 2004, Seroquel, Geodon, and Abilify sequentially won approval for the treatment of manic episodes in bipolar disorder.
Philip G. Janicak, M.D.
Professor of Psychiatry, Rush University Medical Center
Dr. Janicak has disclosed that he is a member of the speakers bureau of Abbott, Astra-Zeneca, Bristol-Myers Squibb, Janssen, and Pfizer, that he is a consultant for Astra-Zeneca, Bristol-Myers Squibb, Janssen, and Pfizer, and that he has received grant/research support from Astra-Zeneca, Bristol-Myers Squibb, Janssen, Neuronetics, and Sanofi-Synthelabo. Dr. Janicak has disclosed that propranolol has not been approved by the U.S. Food and Drug Administration for use in the treatment of agitation. Please consult product labeling for the approved usage.
Dr. Janicak, you've had a long career in research and academia, and I was hoping you could help shed some light on the various contentious issues surrounding the use of atypical antipsychotics, including the issue of whether there is clearly a difference in metabolic profile among the different medications.
We may think of clozapine as a drug of the ‘90s, but Sandoz began research on the drug in the early ‘60s, and the first paper appeared in 1966, the Medical Journal of Vienna.
Daniel Carlat, MDDr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
I know what you're thinking, "This is going to be a Cymbalta vs. Effexor article, and Cymbalta will get another TCR drubbing as it did last year." Not quite. In fact, there are two major battles to be reviewed: Effexor vs. Cymbalta, but probably more relevant, Effexor vs. Lexapro.
Daniel Carlat, MDDr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
The notion that passing magnets over people's heads could make them happier has been around for a very, very long time, at least since the 1770s. The Viennese physician Franz Anton Mesmer used the technique in front of large 18th century audiences, and was so successful that Louis XVI funded the establishment of a "Magnetic Institute" in France to work on the technique further.
Daniel Carlat, MDDr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
Very quietly, under our very noses, most of the newer antidepressants have gone generic, the latest being Celexa (citalopram). Before more details, here is a little generics review for those of you who have not been keeping up with this ferociously litigious area of psychopharmacology.
KarXT (Cobenfy) is the first antipsychotic that doesn’t block dopamine. We trace the origins of this new drug to a South Asian herb used for over 5,000 years, up to the three...